Go Back   ITalkCash.com - Forum for financial investments > Public Investment > Penny Stocks
Forum Register Calendar Search Today's Posts Mark Forums Read

FDA Decision & PIII Data in 3Q 2010 = Top Pick - penny stocks

Reply
 
LinkBack Thread Tools Display Modes
Old 08-05-2010, 09:29 AM
New Investor
 
Join Date: Aug 2010
Posts: 4
Default FDA Decision & PIII Data in 3Q 2010 = Top Pick

FDA approval for Econiche (E.coli Vaccine) & Urocidin (Bladder Cancer) Phase 3 results in 3Q 2010 !! Bioniche has tremendous upside Potential .Please do your own Homework.

Bioniche Has The Potential To Become The Next 10-Bagger .Good Luck to All !!!!!!



Bioniche Life Science (BNC.TO) Canadian Stock !!

Market Cap: 76 Mio $
Cash: 22 Mio $
Price: 1,08 $


Dundee Sec with Buy-Rating (June 2010)....

Bioniche has three businesses with diversified risk/reward profiles:Animal Health, which is expected to generate around $28 million in salesin fiscal 2010; Human Health, with Phase 3 results expected in mid-2010from lead product, Urocidin, testing for bladder cancer; and FoodSafety, with Canadian approval and a conditional license pending in theU.S. of a vaccine for reducing E. coli 0157 in cattle feces, and apipeline of other vaccines.

Mr. Martin points out that Urocidin provides the “biggest upsidepotential” for Bioniche investors. His initial diligence suggests thatUrocidin has a “relatively high overall probability of approval,” eventhough the first of two planned Phase 3 trials has a moderate level ofrisk, as the refractory patients enrolled in the trial are a“tougher-to-treat” population than was enrolled in the Phase 2 trial, hesays.

Mitigating the risk somewhat is the 20% “complete response” hurdlerequired for Phase 3. That compares with the company’s Phase 2 results,where patients achieved a 46.4% CR rate at 26 weeks in a population thatwas mainly relapsed but also included a few patients being treated forthe first time.

A second planned Phase 3 trial will test Urocidin head-to-head againstthe current standard of care, baccilus Calmette-Guerin (BCG) infirst-line treatment, “where we expect Urocidin to demonstrate betterefficacy, based on prior data, and superior safety and tolerability,” hepredicts.

In 2009, Bioniche licensed Urocidin’s U.S. commercial rights to EndoPharmaceuticals. Based on incidence of bladder cancer and possiblepricing, he figures the global market opportunity for Urocidin in therefractory population could be $800 million. If the second Phase 3 trialexpands the Urocidin label to first-line treatment, the marketopportunity could grow to an estimated $2 billion.

“Twenty-five percent penetration of this market would represent $500million in annual sales and an estimated $112.5 million in gross profitfor Bioniche,” Mr. Martin says .

--------------------------------------------------------------------

Bioniche to Get up to $130M in Urology Deal with Endo
BioWorld Today


Crystal Research 18.02.2010
http://www.crystalra.com/pdf/BNC_2QF...e_02-18-10.pdf


Urocidin Potential New Treatment for Bladder Cancer
Urocidin Potential New Treatment for Bladder Cancer, Page 3 of 4 - Associated Content - associatedcontent.com


Some Positive Signs ..

UPDATE 1-Bioniche gets $6 mln milestone payment from Endo Pharma
UPDATE 1-Bioniche gets $6 mln milestone payment from Endo Pharma | Reuters
---


Bioniche obtains two additional milestones under licensing agreement with Endo
Bioniche obtains two additional milestones under licensing agreement with Endo | TradingMarkets.com
--


All DMC (Data Monitoring Committee) are Positive !!!!

Bioniche Phase III Clinical Trial With Urocidin(TM) Given Continued Green Light By DMC
Bioniche Phase III Clinical Trial With Urocidin(TM) Given Continued Green Light By DMC



Only 105 patients in current PIII !!!!

In November 2008,
during a meeting of urologists in Santigo Chile, the biopharmaceutical research company presented positive clinical studies (one and two) involving 130 bladder cancer patients treated with Urocidin. Elderly patients (average 73 years old) during the clinical studies noted excellent safety results .



Upcoming Milestones 2010

2009/2010 Conditional license for E. coli cattle vaccine in the U.S.

2009/2010 Achievement of pre-commercialization milestone payments for
UrocidinTM

2010 First U.S. sales of E. coli cattle vaccine

2010 Results of refractory Phase III bladder cancer trial

2011 Belleville, ON vaccine manufacturing centre operational
..
Reply With Quote
Old 08-05-2010, 10:36 AM
New Investor
 
Join Date: Aug 2010
Posts: 1
Default

Thanks for the update.
Reply With Quote
Old 09-13-2010, 02:34 PM
ItalkCash User
 
Join Date: Sep 2010
Posts: 12
Default

Guaranteed new ideas with simple ways on having good stock picks to be able to gain more!

pennyalerts./info

Copy and paste the link above without the / to get MORE info
Reply With Quote
Reply

Thread Tools
Display Modes


Lotto Premium Bonds Book hotel room.



Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2012, vBulletin Solutions, Inc.
Search Engine Friendly URLs by vBSEO 3.6.0